Structure-activity relationships of novel quinazoline derivatives with high selectivity for HER2 over EGFR

Area of Science:

• Medicinal Chemistry
• Oncology
• Molecular Biology

Background:

• Gene amplification of human epidermal growth factor receptor 2 (HER2) drives proliferation and progression in various cancers.
• Current HER2 inhibitors like lapatinib lack selectivity, inhibiting wild-type EGFR and causing severe adverse effects.
• A critical need exists for highly selective HER2 inhibitors to improve cancer therapy outcomes.

Purpose of the Study:

• To design and synthesize novel quinazoline derivatives with enhanced selectivity for HER2 over wild-type EGFR.
• To investigate the structure-activity relationships governing HER2/EGFR selectivity in these novel compounds.

Main Methods:

• Synthesis of novel quinazoline derivatives.
• Structure-activity relationship (SAR) analysis to determine key structural features for selectivity.
• In vitro evaluation of inhibitory activity against HER2 and EGFR.
• Assessment of anti-proliferative effects on HER2-overexpressing cancer cell lines.

Main Results:

• Novel quinazoline derivatives were successfully designed and synthesized.
• Structure-activity relationship analysis identified critical aniline and C-6 substituents for HER2 selectivity.
• Compound 7c demonstrated potent HER2 inhibition (IC50 = 8 nM) with 240-fold greater selectivity over EGFR compared to lapatinib.
• Synthesized compounds exhibited nanomolar anti-proliferative activity against HER2-overexpressing SKBR3 breast cancer cells.

Conclusions:

• The novel quinazoline derivatives exhibit promising selectivity for HER2 over wild-type EGFR.
• Compound 7c represents a potential lead candidate for developing more targeted HER2-inhibitor therapies.
• These findings offer a foundation for improved cancer treatments with reduced off-target effects.